ConductScience.org, home

Paper38136389

Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.

Viscuse PV and 14 others. Cancers (Basel), 2023. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Papers, record 38136389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38136389

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.22
iCite
Revised in PubMed
2024-02-10
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Viscuse PVPaul Vhttps://orcid.org/0000-0003-0834-8688
2Slack-Tidwell RSRebecca Shttps://orcid.org/0000-0003-3041-8582
3Zhang MMiao
4Rohra PPrih
5Zhu KKeyi
6San Lucas FAF Anthony
7Konnick EErichttps://orcid.org/0000-0001-5904-1788
8Pilie PGPatrick G
9Siddiqui BBilalhttps://orcid.org/0000-0002-6806-1294
10Logothetis CJChristopher J
11Corn PPaul
12Subudhi SKSumit K
13Pritchard CCColin C
14Soundararajan RRama
15Aparicio AAna

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA015704NCI NIH HHSUnited StatesP30CA015704PubMed

Source NIH RePORTER

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131040929Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.Oncotarget2019https://conductscience.org/library/papers/31040929PubMed
235805010Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.Cancers (Basel)2022https://conductscience.org/library/papers/35805010PubMed
324323898Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.Clin Cancer Res2014https://conductscience.org/library/papers/24323898PubMed
428059768SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.Science2017https://conductscience.org/library/papers/28059768PubMed
522156612Modeling a lethal prostate cancer variant with small-cell carcinoma features.Clin Cancer Res2012https://conductscience.org/library/papers/22156612PubMed
616921051
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
J Clin Oncol2006https://conductscience.org/library/papers/16921051PubMed
728411207Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Cancer Discov2017https://conductscience.org/library/papers/28411207PubMed
833163409Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer.Front Oncol2020https://conductscience.org/library/papers/33163409PubMed
99815901Association of p53 mutations with metastatic prostate cancer.Clin Cancer Res1995https://conductscience.org/library/papers/9815901PubMed
1033339136Neuroendocrine and Aggressive-Variant Prostate Cancer.Cancers (Basel)2020https://conductscience.org/library/papers/33339136PubMed
1128059767Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.Science2017https://conductscience.org/library/papers/28059767PubMed
1229985747Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.J Clin Oncol2018https://conductscience.org/library/papers/29985747PubMed
1331515154Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol2019https://conductscience.org/library/papers/31515154PubMed
1429029453PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Oncotarget2017https://conductscience.org/library/papers/29029453PubMed
1535294956Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.PLoS One2022https://conductscience.org/library/papers/35294956PubMed
1624189654Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.J Mol Diagn2014https://conductscience.org/library/papers/24189654PubMed
1728446506Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.Clin Cancer Res2017https://conductscience.org/library/papers/28446506PubMed
1824535589Small cell carcinoma of the prostate.Nat Rev Urol2014https://conductscience.org/library/papers/24535589PubMed
1925225419
Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
J Clin Oncol2014https://conductscience.org/library/papers/25225419PubMed
208023157Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.Science1994https://conductscience.org/library/papers/8023157PubMed

See all 28 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42220083MITF Gain-of-Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance.Cancer Rep (Hoboken)2026https://conductscience.org/library/papers/42220083PubMed
39796175The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.Int J Mol Sci2025https://conductscience.org/library/papers/39796175PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene
RB15925PubTator's text mininghttps://conductscience.org/library/genes/5925NCBI Gene
REV151455PubTator's text mininghttps://conductscience.org/library/genes/51455NCBI Gene
TERT7015PubTator's text mininghttps://conductscience.org/library/genes/7015NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38136389

GET https://conductscience.org/api/papers/v1/38136389/references?page=2